Two 12-week phase 3 trials and a 43-week extension will test 8 mg and 16 mg HLP003 added to antidepressants, with APPROACH enrollment now complete.
|Articles|September 16, 2008
- March15 2003
- Volume 10
- Issue 5
PHARMACEUTICAL STOCKWATCH
Advertisement
Articles in this issue
about 18 years ago
Know the Seven Sins of Practice Marketingabout 18 years ago
Don't Take Your Listing for Grantedabout 18 years ago
Offer an Easier Cholesterol Testabout 18 years ago
The FTC Helps Disconnect Telemarketersabout 18 years ago
Proposed Tax Package Divides Investorsabout 18 years ago
Taxes and Spendingabout 18 years ago
Space Shuttle Doctors Rememberedabout 18 years ago
Hail Columbiaabout 18 years ago
Will Your Savings Be Decimated by LTC?about 18 years ago
BEATING BROKER FEESAdvertisement
Related to this article
This preview of EADV 2026 provides a teaser of new data and interviews being highlighted at this Vienna dermatology conference.
Phase 2b AMPLIFIED data show a 42.7% UACR drop in AMKD with modest proteinuria; AMPLITUDE interim data are due early 2027.
George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.
Advertisement
Advertisement
Trending on HCPLive
1
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
2
ProACt Data Show Early Functional Gains with Adjunctive Cariprazine In MDD
3
FDA Updates Sotatercept Label with HYPERION Data in Early PAH
4
EMBARQ-CSU: Barzolvolimab Meets Primary, Secondary Endpoints in CSU Trials
5